Company research
BICYCLE THERAPEUTICS PLC
CIK 1761612Updated Sep 24, 2026
SecurityBCYC · NASDAQ · adr
Name history
BICYCLE THERAPEUTICS Ltd · through May 24, 2019
BCYC price & chart
Loading TradingView…
NASDAQ:BCYC on TradingView ↗About the company
Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating nuzefatide pevedotin, formerly BT5528, a Bicycle® Drug Conjugate (BDC®) targeting EphA2, a historically undruggable target; a pipeline of other bicycle-based conjugate molecules, including Bicycle® Radioconjugates (BRC®) for radiopharmaceutical use; zelenectide pevedotin (formerly BT8009), a BDC® targeting Nectin-4, a well-validated tumor antigen; and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases in additional therapeutic areas.
In the news
No coverage from other publishers is available.
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Submission of Matters to a Vote of Security Holders
Items 5.07
Other Events
Items 8.01, 9.01
Show 5 more recent filings
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
ARS filing
DEF 14A filing
Other Events
Items 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 717,597,000Source | 956,868,000Source | 595,344,000Source | 410,609,000Source |
| Property, Plant and Equipment, NetUSD | 6,021,000Source | 9,516,000Source | 14,515,000Source | 19,110,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 628,110,000Source | 879,520,000Source | 526,423,000Source | 339,154,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 0Source | 0Source | 0Source | 2,045,000Source |
| Assets, CurrentUSD | 682,885,000Source | 928,605,000Source | 561,868,000Source | 369,383,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 19,181,000Source | 13,432,000Source | 11,406,000Source | 9,022,000Source |
| Operating Lease, Right-of-Use AssetUSD | 15,886,000Source | 7,673,000Source | 13,169,000Source | 13,658,000Source |
| Other Assets, NoncurrentUSD | 12,805,000Source | 11,074,000Source | 5,792,000Source | 8,458,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 107,620,000Source | 163,808,000Source | 224,412,000Source | 139,826,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 894,000Source | 890,000Source | 550,000Source | 387,000Source |
| Additional Paid in CapitalUSD | 1,512,339,000Source | 1,472,842,000Source | 883,446,000Source | 601,105,000Source |
| Retained Earnings (Accumulated Deficit)USD | -899,751,000Source | -680,791,000Source | -511,760,000Source | -331,096,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -3,505,000Source | 119,000Source | -1,304,000Source | 387,000Source |
| Stockholders' Equity Attributable to ParentUSD | 609,977,000Source | 793,060,000Source | 370,932,000Source | 270,783,000Source |
| Liabilities and EquityUSD | 717,597,000Source | 956,868,000Source | 595,344,000Source | 410,609,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 56,984,000Source | 67,230,000Source | 69,537,000Source | 53,342,000Source |
| Operating Lease, Liability, CurrentUSD | 2,551,000Source | 5,328,000Source | 4,876,000Source | 3,125,000Source |
| Accounts Payable, CurrentUSD | 9,669,000Source | 15,793,000Source | 13,050,000Source | 6,472,000Source |
| Operating Lease, Liability, NoncurrentUSD | 14,096,000Source | 3,990,000Source | 9,382,000Source | 10,885,000Source |
| Other Liabilities, NoncurrentUSD | 1,032,000Source | 1,121,000Source | 4,579,000Source | 3,829,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 44,354,000Source | 41,246,000Source | 31,509,000Source | 26,452,000Source |
| Deferred Revenue, CurrentUSD | 2,961,000Source | 10,191,000Source | 24,978,000Source | 20,418,000Source |
| Deferred Revenue, NoncurrentUSD | 35,508,000Source | 91,467,000Source | 110,216,000Source | 41,455,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | 30,698,000Source | 30,315,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | — | — | 30,698,000Source | 30,315,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -218,960,000Source | -169,031,000Source | -180,664,000Source | -112,717,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 6,422,000Source | 7,174,000Source | 6,546,000Source | 3,689,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 39,464,000Source | 38,081,000Source | 32,477,000Source | 26,779,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | -2,482,000Source | 1,641,000Source |
| Increase (Decrease) in Accounts PayableUSD | -6,871,000Source | 3,095,000Source | 8,002,000Source | 2,561,000Source |
| Deferred Income Tax Expense (Benefit)USD | -850,000Source | -5,226,000Source | 3,306,000Source | -4,976,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -249,675,000Source | -164,724,000Source | -60,628,000Source | -86,111,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -2,350,000Source | -1,235,000Source | -2,929,000Source | -18,987,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 2,350,000Source | 1,235,000Source | 2,929,000Source | 18,987,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | -131,000Source | 519,750,000Source | 250,027,000Source | 6,692,000Source |
| Repayments of Long-term DebtUSD | — | 31,863,000Source | — | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | -251,352,000Source | 353,097,000Source | 187,816,000Source | -99,526,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 628,715,000Source | 880,067,000Source | 526,970,000Source | 339,154,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | 1,373,000Source | 2,753,000Source | 2,793,000Source |
| Income Taxes Paid, NetUSD | -717,000Source | 792,000Source | 562,000Source | 2,228,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 39,464,000Source | 38,081,000Source | 32,477,000Source | 26,779,000Source |
| DepreciationUSD | — | — | 6,500,000Source | 3,700,000Source |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 700,000Source | -700,000Source | -600,000Source | -600,000Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | -954,000Source | — | — |
| General and Administrative ExpenseUSD | 79,368,000Source | 72,181,000Source | 60,426,000Source | 49,507,000Source |
| Income Tax Expense (Benefit)USD | 152,000Source | -4,765,000Source | 1,457,000Source | -1,524,000Source |
| InterestExpenseNonoperatingUSD | 206,000Source | 1,730,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -218,960,000Source | -169,031,000Source | -180,664,000Source | -112,717,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -218,960,000Source | -169,031,000Source | -180,664,000Source | -112,717,000Source |
| Nonoperating Income (Expense)USD | 28,257,000Source | 36,076,000Source | 10,739,000Source | 2,412,000Source |
| Operating ExpensesUSD | 319,651,000Source | 245,147,000Source | 216,922,000Source | 131,116,000Source |
| Proceeds from Issuance of Common StockUSD | — | 544,127,000Source | 249,345,000Source | 5,703,000Source |
| Proceeds from Stock Options ExercisedUSD | 37,000Source | 7,528,000Source | 682,000Source | 989,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 72,586,000Source | 35,275,000Source | 26,976,000Source | 14,463,000Source |
| Operating Income (Loss)USD | -247,065,000Source | -209,872,000Source | -189,946,000Source | -116,653,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -218,808,000Source | -173,796,000Source | -179,207,000Source | -114,241,000Source |
| Income Tax Expense (Benefit)USD | 152,000Source | -4,765,000Source | 1,457,000Source | -1,524,000Source |
| Net Income (Loss) Attributable to ParentUSD | -218,960,000Source | -169,031,000Source | -180,664,000Source | -112,717,000Source |
| Earnings Per Share, BasicUSD per share | -3.16Source | -2.9Source | -5.08Source | -3.8Source |
| Earnings Per Share, DilutedUSD per share | -3.16Source | -2.9Source | -5.08Source | -3.8Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 69,279,838Source | 58,207,593Source | 35,592,362Source | 29,660,659Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 69,279,838Source | 58,207,593Source | 35,592,362Source | 29,660,659Source |
| Interest Expense (non-operating)USD | 206,000Source | 1,730,000Source | — | — |
| Additional Financial Items | ||||
| Common Stock, Dividends, Per Share, DeclaredUSD per share | 0Source | 0Source | 0Source | — |
| Current Income Tax Expense (Benefit)USD | 1,002,000Source | 461,000Source | -1,849,000Source | 3,452,000Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | 6,400,000Source | 7,200,000Source | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 700,000Source | -700,000Source | -600,000Source | -600,000Source |
| General and Administrative ExpenseUSD | 79,368,000Source | 72,181,000Source | 60,426,000Source | 49,507,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -225,456,000Source | 5,814,000Source | 3,773,000Source | 2,034,000Source |
| Interest and Other IncomeUSD | 28,463,000Source | 34,284,000Source | 14,002,000Source | 5,756,000Source |
| Interest ExpenseUSD | — | — | 3,263,000Source | 3,344,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -218,960,000Source | -169,031,000Source | -180,664,000Source | -112,717,000Source |
| Nonoperating Income (Expense)USD | 28,257,000Source | 36,076,000Source | 10,739,000Source | 2,412,000Source |
| Operating ExpensesUSD | 319,651,000Source | 245,147,000Source | 216,922,000Source | 131,116,000Source |
| Research and Development ExpenseUSD | 240,283,000Source | 172,966,000Source | 156,496,000Source | 81,609,000Source |
Filing attachments
tm2621593d1_ex99-1.htm · 8-K · 2026-07-30
EX-99.1 2 tm2621593d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results Data presented at AACR and ASCO provide further validation of the potential of Bicycle ® technology to deliver oncology therapeutics with improved benefit/risk profiles compared to existing modalities Expanded Clinical Advisory Board with the addition of Thomas Powles, MBBS, MRCP, M.D. Cash and cash equivalents of $510.1 million as of …
Read attachment ↗tm2615187d1_ex99-1.htm · 8-K · 2026-05-21
EX-99.1 2 tm2615187d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting In the dose optimization stage of the randomized Phase 2 trial (Duravelo-2), zelenectide pevedotin at its optimal dose in combination with pembrolizumab demonstrated response rates comparable to published data for standard of care (SOC) in patients with previously untreated metastatic urothelial cancer (mUC) The optimal dose of zelenectide demonstr…
Read attachment ↗tm2613019d1_ex99-1.htm · 8-K · 2026-04-30
EX-99.1 2 tm2613019d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results Presentations at AACR Annual Meeting 2026 underscore significant opportunities for nuzefatide pevedotin in EphA2 expressing cancers, including pancreatic cancer Human imaging data provides further evidence of the potential of EphA2 as a novel cancer target and the positive properties of Bicycle ® radioligand molecules for radiopharmaceut…
Read attachment ↗tm2612166d1_ex99-1.htm · 8-K · 2026-04-20
EX-99.1 2 tm2612166d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026 Phase 1 combination data of 6.5mg/m2 Q2W nuzefatide pevedotin plus nivolumab demonstrate an encouraging preliminary efficacy profile with a differentiated tolerability profile in previously treated metastatic urothelial cancer Nuzefatide pevedotin demonstrates potent preclinical anti-tumor activity across a broad range o…
Read attachment ↗tm268887d1_ex99-1.htm · 8-K · 2026-03-17
EX-99.1 2 tm268887d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results Phase 2/3 Duravelo-2 pivotal trial evaluating zelenectide pevedotin (zelenectide) plus pembrolizumab in metastatic urothelial cancer (mUC) successfully identifies 6mg/m 2 zelenectide two weeks on, one week off dose (6mg dose) as optimal, demonstrating response rates comparable to published rates for standards of care with a …
Read attachment ↗